- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02545478
Biomarkers in Infection
Early Detection of Inflammatory Biomarkers in Infection
Studieoversikt
Status
Forhold
Detaljert beskrivelse
The body's immune system and a subsequent inflammatory response are triggered during infection. The detection of an activated immune system, and an indication of the degree of the host response, is helpful to the clinician both in assessing the severity of infection and in patient treatment and management. Currently, the white blood cell count and the differential are the most common laboratory parameters for measuring host response. The sedimentation rate and CRP are also used to detect inflammation. However, these tests are all imperfect predictors, and a test providing a better assessment of immune response would be helpful to the clinician in patient care. Additionally, understanding host response to infection may be helpful in understanding the biology and pathophysiology of sepsis. There are other biomarkers and inflammatory markers that may be found early in the initial presentation of infection such as cytokines (VEGF IL-1,IL-4,IL-6, IL-10, PAF, TNF, lectins iNoS,etc.) and clotting factors (protein C, d-dimer, complements involved in the clotting cascade, CRP, etc) that may provide a means of early detection of systemic inflammation, cell dysfunction, and related conditions. Early identification of patients at risk for systemic inflammatory syndromes, sepsis and septic shock may help direct patients to earlier antibiotic administration and early intervention with goal directed therapy. It may also serve as a tool for risk stratification when components such as age, comorbid illness and infection type are included.
The endothelium and endothelial cell markers are important in sepsis, yet a somewhat under-studied field of research. Additionally, the endothelium is a key regulator of the microcirculation, a place where oxygen diffusion occurs. One focus of this study is to measure endothelial markers (ie VEGF) and other cytokines with the goal of correlating these markers with severity of sepsis. Another focus is to study the response of various components in the blood, including the leukocytes, red cells, the endothelium, as well as cellular components such as the mitochondria. We will specifically look at alterations in thiamine, Vitamin D, CoQ10,l-carnitine and other nutrients as part of (and as related to) the body's response. Recently, a non-invasive method of assessing microvascular circulation by orthogonal polarization spectral (OPS) imagery has become available using a non-invasive technology known as orthogonal polarization spectroscopy. This technique enables direct visualization and quantification of microcirculatory blood flow, and represents an important surrogate outcome to which endothelial cell marker may be correlated. This will involve placing the microscopy probe gently against the sublingual mucosa and collecting a videotape of the circulation lasting about twenty seconds. This process involves minimal (or no) risk - it is akin to taking a temperature and uses no radiation. This videotape will be examined later by a novel software program that quantifies the circulation and used as an important surrogate outcome measure. Additionally, we are going to perform echocardiography to better understand the heart's response to sepsis, and correlated the molecular responses that we find with the changes in the responses by the heart.
This is a multicenter, observational pilot study which aims to evaluate how early biomarkers of infection an inflammation perform in identifying patients at risk for poor outcomes in sepsis and septic shock. The study will utilize a cohort of patients presenting to the ED with suspected infection as well as non-infected control population.
These patients will be compared with a non-infected population.
Enrolled subjects in the infected group will have blood samples and chart review obtained at enrollment, 24, 48 and 72 hours. For the control group, only a single blood draw will be collected at enrollment.
Enrolled subjects will also undergo physiologic assessments using echocardiography, Microscan, Non-invasive cardiac output monitor (NICOM), extremity temperature as well as End-Tidal C02 measurements if a trained researcher is present.
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiekontakt
- Navn: Nathan Shapiro, MD MPH
- Telefonnummer: 617-754-2343
- E-post: nshapiro@bidmc.harvard.edu
Studer Kontakt Backup
- Navn: Sharon R Hayes, RN
- Telefonnummer: 617-754-2334
- E-post: srhayes@bidmc.harvard.edu
Studiesteder
-
-
-
Aarhus, Danmark
- Har ikke rekruttert ennå
- Aarhus Universitetshospital
-
Ta kontakt med:
- Hans Kirkegaard
- E-post: Hans Kirkegaard <hanskirkegaard@dadlnet.dk>
-
Hovedetterforsker:
- Hans Kirkegaard, MD
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Rekruttering
- Beth Israel Deaconess Medical Center
-
Ta kontakt med:
- Nathan Shapiro, MD MPH
- Telefonnummer: 617-754-2343
- E-post: nshapiro@bidmc.harvard.edu
-
Boston, Massachusetts, Forente stater, 02114
- Aktiv, ikke rekrutterende
- Massachusetts General Hospital
-
Boston, Massachusetts, Forente stater, 02215
- Aktiv, ikke rekrutterende
- Brigham and Women's Hospital
-
Worcester, Massachusetts, Forente stater, 01608
- Rekruttering
- St. Vincent's Hospital
-
Ta kontakt med:
- David Miru, RN
- Telefonnummer: 508-363-5286
- E-post: dmiru@bidmc.harvard.edu
-
Ta kontakt med:
- Pamel Sigel, RN
- Telefonnummer: 508-363-7018
- E-post: PAMELA.SIGEL@stvincenthospital.com
-
Hovedetterforsker:
- Nathan Shapiro, MD MPH
-
-
New York
-
Brooklyn, New York, Forente stater, 11215
- Rekruttering
- New York Methodist Hospital
-
Ta kontakt med:
- Robert Birkhahn, MD
-
Hovedetterforsker:
- Rorber Birkhahn, MD
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37232
- Rekruttering
- Vanderbiltt University
-
Ta kontakt med:
- Wesley Self, MD
- Telefonnummer: 615-936-0253
- E-post: wesley.self@vanderbilt.edu
-
Hovedetterforsker:
- Wesley Self, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria for Infected subjects:
- Age 18 years of age or older
- Confirmed or suspected infection
Inclusion Criteria for Control Subjects:
- Age 18 years of age or older
- A non-infectious clinical presentation to include
- Normal white blood cell count ( > 4,000 and/or < 12,000)
- Normothermia ( > 96.5 and/or less 100.4)
- Absence of the following clinical complaints: productive cough, fever, pyuria, rash
- No evidence of acute coronary syndrome
Exclusion Criteria for Control Subjects:
- Suspected infection
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Infected Group
subjects with suspected infection
|
Non-infected group
subjects without any infection
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
28 day in-hospital mortality
Tidsramme: within 28 days after inclusion
|
participants will be followed up for 28 days
|
within 28 days after inclusion
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Organ Dysfunction assessed by Sepsis-related Organ Failure Assessment (SOFA) Score
Tidsramme: within 24 hours
|
within 24 hours
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Nathan Shapiro, MD MPH, Beth Israel Deaconess Medical Center
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2005P000116
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Sepsis
-
University of Kansas Medical CenterUniversity of KansasRekrutteringSepsis | Septisk sjokk | Sepsis syndrom | Sepsis, alvorlig | Sepsis bakterie | Sepsis bakteriemiForente stater
-
Jip GroenInBiomeRekrutteringMikrobiell kolonisering | Neonatal infeksjon | Neonatal sepsis, tidlig debut | Mikrobiell sykdom | Klinisk sepsis | Kultur negativ neonatal sepsis | Neonatal sepsis, sent debut | Kultur Positiv neonatal sepsisNederland
-
The University of QueenslandRoyal Brisbane and Women's HospitalUkjent
-
Karolinska InstitutetÖrebro University, SwedenFullførtSepsis | Sepsis syndrom | Sepsis, alvorligSverige
-
Ohio State UniversityFullførtSepsis, alvorlig sepsis og septisk sjokkForente stater
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsFullførtSepsis | Septisk sjokk | Alvorlig sepsis | Sepsis syndromStorbritannia
-
Indonesia UniversityFullførtAlvorlig sepsis med septisk sjokk | Alvorlig sepsis uten septisk sjokkIndonesia
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRekrutteringAlvorlig sepsis | Alvorlig sepsis uten septisk sjokkForente stater
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian... og andre samarbeidspartnereFullførtSepsis | Septisk sjokk | Alvorlig sepsis | Infeksjon | Sepsis syndromForente stater
-
Inverness Medical InnovationsFullførtSepsis | Systemisk inflammatorisk responssyndrom | Alvorlig sepsis | Sepsis syndromForente stater